What the FDA labels say about taking them together
Colchicine and fenofibrate
Colchicine's FDA label of July 22, 2025 names fenofibrate in its warnings and precautions section, and fenofibrate's label names colchicine too. The fenofibrate label: “Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates.”
Check it at the source: the colchicine FDA label on DailyMed (effective July 22, 2025, Aurobindo Pharma Limited); the fenofibrate FDA label on DailyMed (effective April 29, 2024, A-S Medication Solutions).
What does the colchicine label say about fenofibrate?
Colchicine label, warnings and precautionsConcomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid or benzafibrate (themselves associated with myotoxicity) or cyclosporine with colchicine may potentiate the development of myopathy [see Drug Interactions (7) ].
Source: FDA drug label (Colchicine), Aurobindo Pharma Limited, effective July 22, 2025 (SPL set dd93a40f-92ab-47ac-9083-b8a7a0b18ad6), via openFDA; the full label on DailyMed
What does the fenofibrate label say about colchicine?
Fenofibrate label, drug interactionsCases of myopathy, including rhabdomyolysis, have been reported with fenofibrates co-administered with colchicine, and caution should be exercised when prescribing fenofibrate with colchicine.
Antara label (Lupin Pharmaceuticals, Inc., October 1, 2025), drug interactionsClinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates. Intervention: Consider if the benefit of using colchicine concomitantly with Antara outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of …
Antara label (Lupin Pharmaceuticals, Inc., October 1, 2025), warnings and precautionsConsider whether the benefit of using colchicine concomitantly with Antara outweighs the increased risk of myopathy. [ see Drug Interactions ( 7 )].
Source: FDA drug label (Antara, NDA021695), Lupin Pharmaceuticals, Inc., effective October 1, 2025 (SPL set 24790a18-0291-4b88-a724-acac43b616ce), via openFDA
Source: FDA drug label (Tricor), NDA021656 (Abbvie), as published by A-S Medication Solutions, effective April 29, 2024 (SPL set 84b2af1b-365e-4723-ac5f-bc826ec47772), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Colchicine | Fenofibrate | |
|---|---|---|
| Labeled for | Gout | High cholesterol, High triglycerides |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.122 per tablet 0.6 mg tablet | $0.103 per tablet 160 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once